Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Nadolol × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Cirrhosis 1 Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 27 Capecitabine 25 Irinotecan 18 Fluorouracil 18 tislelizumab 16 Paclitaxel 13 S 1 (combination) 11 Radiotherapy 11 Cisplatin 11 Bevacizumab 11 apatinib 10 Leucovorin 9 Laparoscopy 8 Endoscopic Mucosal Resection 8 Drug Therapy 8 Cetuximab 8 Docetaxel 7 sintilimab 6 XELOX 6 Radiation 6 Propranolol 6 Neoadjuvant Therapy 6 Immune Checkpoint Inhibitors 6 Gemcitabine 6 camrelizumab 5 Surgical Procedures, Operative 5 Nivolumab 5 HMPL-013 5 Folfox protocol 5 Levoleucovorin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00567216 2010-06-08

GVO-nadolol

Taipei Veterans General Hospital, Taiwan

Phase 4 Unknown

Gastrointestinal

Carcinoma, Hepatocellular, Liver Cirrhosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡